Drug Profile
Research programme: RNAi therapeutics - Genesis Research and Development
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genesis Research and Development
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
- Discontinued Asthma; Atopic dermatitis; Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in New Zealand
- 14 Mar 2008 Discontinued - Preclinical for Allergy in New Zealand (unspecified route)
- 14 Mar 2008 Discontinued - Preclinical for Asthma in New Zealand (unspecified route)